ERBB2 and breast carcinoma: Elevated levels of human epidermal growth factor receptor-2 (HER-2) are seen in between 20 and 25% of breast cancer (BC) cases, resulting in an invasive tumor phenotype and associated with inferior clinical prognosis1–3.